89 results
Page 2 of 5
8-K
EX-99.1
za6afdno5elkf2biwgg
2 Nov 23
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
5:10pm
424B4
klmkangvv2onsq
1 Nov 23
Prospectus supplement with pricing info
5:09pm
8-K
EX-99.1
xjrzdd9ezy38kg
10 Oct 23
Patent Application Filed with Potential to Extend AmeluzĀ® Protection to 2043
9:15am
8-K
EX-99.1
1oi2ll94g cuk
4 Oct 23
Biofrontera Inc. Announces Preliminary Third Quarter Revenues
8:45am
8-K
EX-99.1
e7s21ee
3 Oct 23
Other Events
5:17pm
8-K
EX-99.1
os2yu6gdby29ayz
11 Aug 23
Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update
7:30am
8-K
EX-99.1
t4g7xhmlkx
13 Jul 23
Management Reaffirms Full-Year 2023 Revenue Growth of at least 25% over Prior Year
12:00am
8-K
EX-99.1
jyd3woucl8h
12 Jul 23
Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors
8:44am
8-K
EX-99.1
2lhknz7
3 Jul 23
Biofrontera Inc. Announces 1-for-20 Reverse Stock Split
9:25am
8-K
EX-99.1
r27co
1 Jun 23
Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with AmeluzĀ®-PDT
9:15am
8-K
EX-99.1
hlv m8jqq9gxh6e4
30 May 23
Biofrontera Inc. Names Founder and Executive Chairman Hermann
9:00am
8-K
o833qyrbggmc3zivkx
26 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:12pm
8-K
EX-99.2
y0omvgzac220of75y
12 May 23
Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update
8:09am
8-K
EX-99.1
4cn07n
12 May 23
Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update
8:09am
424B3
j55g jabyqxs
15 Nov 22
Prospectus supplement
5:28pm
424B3
ld1fsvvefyuo8df2 hun
15 Nov 22
Prospectus supplement
5:27pm